Genetic Engineering & Biotechnology News

JUL 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 36 of 45

View It Now! On Demand DURATION: 60 minutes COST: Complimentary Speakers Addressing Challenges of NGS Data Interpretation for Hematologic Malignancies As next-generation sequencing (NGS) technologies continue to rapidly enter the clinical arena, investigators are facing the challenges of transitioning this powerful genomic tool from a benchtop gene discovery method to a routine precision medicine diagnostic. Moreover, the application of NGS to hematologic malignancies has uncovered many underlying molecular mechanisms of disease diagnosis, progression, and response to therapeutic interventions. Yet, with the overwhelming amount and complexity of genomic data that NGS provides, clinicians often get mired in the analysis phase, seeking information that enables them to efficiently utilize the data to provide more effective treatment strategies for their patients. Join us for this groundbreaking Clinical OMICs roundtable webinar, where we will discuss how NGS technologies have aided clinicians in the diagnosis and treatment of hematologic cancers, in addition to discussing strategies employed to streamline the clinical interpretation. A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists. Who Should Attend • Cancer researchers • Scientists using next-generation sequencing • Clinical geneticists • Molecular pathologists • Drug development researchers • Oncologists • Bioinformaticists Free Registration! You Will Learn • How NGS is currently being used by oncologists and geneticists as a diagnostic, prognostic and predictive tool for the treatment of hematologic malignancies • Some of the main challenges in testing and clinical interpretation and how researchers and clinicians are successfully navigating these hurdles • The importance of combining NGS techniques with other testing modalities Andrew Lane, M.D., Ph.D. Physician-Scientist Dana-Farber Cancer Institute Gregory Riedlinger, M.D., Ph.D. Assistant Professor of Pathology, Rutgers Cancer Institute of New Jersey Produced with support from Webinars Kristen Champion, Ph.D. Technical Director Molecular Pathology Laboratory, Med Fusion Sheryl Krevsky Elkin, Ph.D. Scientific Director N-of-One

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - JUL 2017